La Jolla Pharmaceutical Company, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for life-threatening diseases. The company engages in developing LJPC-501, an angiotensin II for the potential treatment of catecholamine-resistant hypotension and hepatorenal syndrome; and GCS-100, a galectin-3 inhibitor for the potential treatment of chronic kidney disease. It also develops LJPC-1010 galectin-3 inhibitor for the potential treatment of nonalcoholic steatohepatitis and other diseases characterized by tissue fibrosis; and LJPC-401, a hepcidin for the potential treatment of hemochromatosis and beta thalassemia. La Jolla Pharmaceutical Company was founded in 1989 and is headquartered in San Diego, California.